Biodegradable micro-osmotic pump for long-term and controlled release of basic fibroblast growth factor.
Microelectromechanical system (MEMS) technology not only provides the possibility of integration of multiple functions but also enables more precise control of dosing of therapeutic agents when the therapeutic window is very limited. Local delivery of basic fibroblast growth factor (bFGF) over a specific dose and time course is critical for mesenchymal tissue regeneration. However, bFGF is degraded quickly in vivo and difficulty of controlling the dose level impedes its effective use in angiogenesis and tissue regeneration. We constructed biodegradable micro-osmotic pumps based on MEMS technology for long-term controlled release of bFGF. The devices were constructed by micro-molding and thermal assembly of 85/15 poly(L-lactide-co-glycolide) sheets. The release of bFGF was regulated at 40 ng/day for four weeks; bioactivity was assessed by monitoring the growth of 3T3 fibroblasts. The proposed devices can be further miniaturized and used for the delivery of multiple therapeutic agents at the individual releasing schedules.
Ryu
WonHyoung
W
Rapid Prototyping Laboratory, Mechanical Engineering Department, 440 Escondido Mall, Bldg. 530, Rm 226, Stanford University, Stanford, CA 94305, USA. whryu@stanford.edu
Huang
Zhinong
Z
Prinz
Fritz B
FB
Goodman
Stuart B
SB
Fasching
Rainer
R
D020341:Absorbable Implants; D000818:Animals; D016503:Drug Delivery Systems / Q000295:instrumentation / Q000379:methods*; D004343:Drug Implants; D004867:Equipment Design; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000493:pharmacokinetics; D051379:Mice; D008954:Models, Biological; D008970:Molecular Weight; D009995:Osmosis; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics
D004343:Drug Implants; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2